Sort

Search

01/05/2022 Marginal zone lymphoma under anti-TNF treatment in Crohn disease
González-Muñoza C, Briones J, Sang Park H, García-Planella E. Marginal zone lymphoma under anti-TNF treatment in Crohn disease. Gastroenterologia y Hepatologia. 2022; 45(5)DOI:10.1016/j.gastrohep.2021.05.010. PMID:34118314. IF:1.900(Q4/10D).
01/05/2022 Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
Garcia-Fortes, M, Hernandez-Boluda, JC, Alvarez-Larran, A, Raya, JM, Angona, A, Estrada, N, Fox, L, Cuevas, B, Garcia-Hernandez, MC, Gomez-Casares, MT, Ferrer-Marin, F, Saavedra, S, Cervantes, F, Garcia-Delgado, R. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers. 2022; 14(9)DOI:10.3390/cancers14092331. PMID:35565461. IF:5.200(Q2/3D).
01/05/2022 Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers
Arranz, MJ, Salazar, J, Bote, V, Artigas-Baleri, A, Serra-LLovich, A, Trivino, E, Roige, J, Lombardia, C, Cancino, M, Hernandez, M, Cendros, M, Duran-Tauleria, E, Maraver, N, Hervas, A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. Pharmaceutics. 2022; 14(5)DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5.400(Q1/2D).
01/05/2022 Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Reinoso-Segura, M, Caballero-Velazquez, T, Herrera, P, Patriarca, F, Fanin, R, Bruno, B, Einsele, H, Nahi, H, Granell, M, Lopez-Corral, L, Reguera, JL, Garcia-Cadenas, I, Gahrton, G, Perez-Simon, JA. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5)DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3.200(Q2/5D).
01/05/2022 An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022)
Jimenez, AJM, De Lima, M, Komanduri, KV, Wang, TP, Zhang, MJ, Chen, KR, Abdel-Azim, H, Abid, MB, Aljurf, M, Alkhateeb, H, Assal, A, Bacher, U, Baron, F, Battiwalla, M, Beitinjaneh, A, Bejanyan, N, Bhatt, VR, Byrne, M, Cahn, JY, Cairo, M, Castillo, P, Copelan, E, DeFilipp, Z, Perez, MAD, Elsawy, M, Gale, RP, George, B, Grunwald, MR, Hildebrandt, GC, Hogan, WJ, Kanakry, CG, Kansagra, A, Kharfan-Dabaja, MA, Khera, N, Krem, MM, Lazaryan, A, Maakaron, J, Martino, R, McGuirk, J, Michelis, FV, Milone, G, Mishra, A, Murthy, HS, Mussetti, A, Nathan, S, Nishihori, T, Olsson, RF, Palmisiano, N, Patel, S, Saad, A, Seo, S, Sharma, A, Solh, M, Verdonck, LF, Wirk, B, Yared, JA, Litzow, M, Kebriaei, P, Hourigan, CS, Saber, W, Weisdorf, D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis (Mar, 10.1038/s41409-022-01625-6, 2022). BONE MARROW TRANSPLANTATION. 2022; 57(5)DOI:10.1038/s41409-022-01625-6. PMID:35297406. IF:4.800(Q1/2D).
01/05/2022 Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source The Young ESUS Longitudinal Cohort Study
Perera, KS, Boasquevisque, DD, Rao-Melacini, P, Taylor, A, Cheng, A, Hankey, GJ, Lee, S, Fabregas, JM, Ameriso, SF, Field, TS, Arauz, A, Coutts, SB, Arnold, M, Mikulik, R, Toni, D, Mandzia, J, Veltkamp, RC, Meseguer, E, Haeusler, KG, Hart, RG, Young ESUS Investigators. Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source The Young ESUS Longitudinal Cohort Study. JAMA Neurology. 2022; 79(5)DOI:10.1001/jamaneurol.2022.0048. PMID:35285869. IF:29.000(Q1/1D).